Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acoltremon Tear Production Measurement Study
NCT05497479Phase 1Completed
- Sponsor
- Aerie Pharmaceuticals
- Start
- Dec 2021
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in dry eye disease (DED) comparing Acoltremon 0.003% with Vehicle (2 arms). Primary endpoints: Unanesthetized Schirmer test at Day 1 and Anesthetized Schirmer test at Day 1. Started Dec 2021; status: completed.
02
Drugs
acoltremon
03
Conditions
dry eye disease (DED)
Beyond the preview
Go deeper on NCT05497479.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05497479.